REGN7544 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postural Orthostatic Tachycardia Syndrome (POTS)
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS)
Trial Timeline
Nov 13, 2024 → Jun 11, 2026
NCT ID
NCT06593600About REGN7544 + Placebo
REGN7544 + Placebo is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Postural Orthostatic Tachycardia Syndrome (POTS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06593600. Target conditions include Postural Orthostatic Tachycardia Syndrome (POTS).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06593600 | Phase 2 | Recruiting |
Competing Products
6 competing products in Postural Orthostatic Tachycardia Syndrome (POTS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ivabradine + Placebo | Amgen | Phase 3 | 76 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Efgartigimod + Placebo | Argenx | Phase 2 | 49 |
| Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo | Lundbeck | Phase 2 | 49 |
| IVIG + Albumin | Grifols | Phase 1/2 | 38 |